A Splice Code for trans-Synaptic Cell Adhesion Mediated by Binding of Neuroligin 1 to α- and β-Neurexins  by Boucard, Antony A. et al.
Neuron, Vol. 48, 229–236, October 20, 2005, Copyright ª2005 by Elsevier Inc. DOI 10.1016/j.neuron.2005.08.026ReportA Splice Code for trans-Synaptic
Cell Adhesion Mediated by Binding
of Neuroligin 1 to a- and b-NeurexinsAntony A. Boucard,1 Alexander A. Chubykin,1
Davide Comoletti,4 Palmer Taylor,4
and Thomas C. Su¨dhof1,2,3,*
1Center for Basic Neuroscience
2Department of Molecular Genetics
3Howard Hughes Medical Institute
The University of Texas Southwestern Medical Center
6000 Harry Hines Boulevard NA4.118
Dallas, Texas 75390
4Department of Pharmacology
University of California, San Diego
9500 Gilman Drive
La Jolla, California 92093
Summary
Previous studies suggested that postsynaptic neuro-
ligins form a trans-synaptic complex with presynaptic
b-neurexins, but not with presynaptic a-neurexins.
Unexpectedly, we now find that neuroligins also bind
a-neurexins and that a- and b-neurexin binding by
neuroligin 1 is regulated by alternative splicing of neu-
roligin 1 (at splice site B) and of neurexins (at splice
site 4). In neuroligin 1, splice site B is a master switch
that determines a-neurexin binding but leaves b-neu-
rexin binding largely unaffected, whereas alternative
splicing of neurexins modulates neuroligin binding.
Moreover, neuroligin 1 splice variants with distinct
neurexin binding properties differentially regulate syn-
aptogenesis: neuroligin 1 that binds only b-neurexins
potently stimulates synapse formation, whereas neu-
roligin 1 that binds to both a- and b-neurexins more
effectively promotes synapse expansion. These find-
ings suggest that neuroligin binding to a- and b-neu-
rexins mediates trans-synaptic cell adhesion but has
distinct effects on synapse formation, indicating that
expression of different neuroligin and neurexin iso-
forms specifies a trans-synaptic signaling code.
Introduction
Neurexins and neuroligins are pre- and postsynaptic
cell surface proteins, respectively, that may function
as trans-synaptic cell adhesion molecules (Ushkaryov
et al., 1992; Ichtchenko et al., 1995, 1996; Song et al.,
1999; Varoqueaux et al., 2004; reviewed in Yamagata
et al., 2003). Vertebrates contain three large neurexin
genes, each of which expresses longer a- and shorter
b-neurexins, producing six principal neurexins (neu-
rexins 1a, 2a, 3a and 1b, 2b, 3b; Ushkaryov et al.,
1992, 1994; Rowen et al., 2002; Tabuchi and Su¨dhof,
2002; Figure 1A). These six principal neurexins are
diversified by extensive alternative splicing at five con-
served sites (referred to as splice sites 1 to 5), resulting
in up to 1000 variants (Ullrich et al., 1995). Neuroligins
were identified based on their binding to b-neurexins
and differ from neurexins in that they have a relatively
*Correspondence: thomas.sudhof@utsouthwestern.edusimple structure and are only differentially spliced at
two positions (splice sites A and B; Figure 2A; Ichtchenko
et al., 1995, 1996).
Neuroligin 1 was found to bind tightly only to b-neu-
rexins that lack an insert in splice site 4 (Ichtchenko
et al., 1995, 1996). In neurexins, splice site 4 is ex-
pressed in variants containing or lacking a 30 residue
insert and is developmentally and spatially regulated
(Ullrich et al., 1995). The synaptic localization and inter-
action of neuroligins and neurexins, including their abil-
ity to mediate cell adhesion (Nguyen and Su¨dhof, 1997),
prompted the hypothesis that postsynaptic neuroligins
form a trans-synaptic complex with presynaptic b-
neurexins (Ichtchenko et al., 1995). This hypothesis
was confirmed by the observation that neuroligin 1,
when expressed in nonneuronal HEK293 cells, induces
presynaptic differentiation in cocultured pontine ex-
plants or hippocampal neurons (Scheiffele et al., 2000;
Fu et al., 2003). Similarly, b-neurexins, when expressed
in nonneuronal cells, induce postsynaptic specializa-
tions in cocultured neurons (Graf et al., 2004). Moreover,
RNA interference studies indicated that ‘‘knockdowns’’
of neuroligins may hinder synapse formation (Chih
et al., 2005). Since neuroligins constitutively dimerize
via their extracellular domain (Comoletti et al., 2003),
they may induce presynaptic differentiation by cluster-
ing b-neurexins (Dean et al., 2003). The importance
of the neuroligin/neurexin complex for normal brain
function is highlighted by the finding that, in humans,
mutations in X-chromosomal neuroligin genes are asso-
ciated with autistic spectrum disorders and/or mental
retardation (Jamain et al., 2003; Yan et al., 2004).
The overexpression and RNA interference experi-
ments suggested a function for b-neurexins and neuroli-
gins in synapse formation but provided little information
about a-neurexins. Knockout (KO) studies revealed that
deletion of a-neurexins was perinatally lethal because
synaptic function was severely impaired without a major
defect in synapse formation (Missler et al., 2003; Zhang
et al., 2005; Kattenstroth et al., 2004). The a-neurexin
KO findings established a role for a-neurexins in mature
synapses that is distinct from the function suggested for
b-neurexins in overexpression studies (Dean et al., 2003;
Graf et al., 2004). However,a- andb-neurexins are largely
composed of the same sequences (Figure 1A), which
would be more consistent with similar instead of radi-
cally different functions. Although further genetic and
overexpression studies likely will help to clarify this co-
nundrum, a major impediment to understanding the
function of neurexins is that little is known about extra-
cellulara-neurexin ligands. At present, the only identified
ligands for a-neurexins are dystroglycan (Sugita et al.,
2001) and neurexophilins (Missler et al., 1998a). Dystro-
glycan, a ubiquitous cell adhesion molecule, performs
an essential function in neurons (Moore et al., 2002)
that, however, does not appear to involve synapse for-
mation (Graf et al., 2004). Neurexophilins are secreted
proteins resembling neuropeptides that may activate
a-neurexin signaling but are not involved in trans-synap-
tic cell adhesion (Missler et al., 1998b).
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neurexin ligands that might be involved in trans-
synaptic cell adhesion. Surprisingly, we identified
neuroligins as major interaction partners of a-neurexins.
We found that a splice variant of neuroligin 1 that lacks
an insert in splice site B and that was not previously
tested (Ichtchenko et al., 1995) avidly interacts with
a-neurexins, as do neuroligins 2 and 3. Neuronal ex-
pression of a neuroligin 1 variant that only binds to b-
neurexins promotes synapse formation more potently,
but synapse expansion less effectively, than a neuroligin
1 variant that binds to both a- and b-neurexins. Our data
thus suggest that a- and b-neurexins may execute
a shared function in trans-synaptic cell adhesion by
Figure 1. Affinity Purification of Neuroligins on Immobilized Neu-
rexin 1a
(A) Domain structures of a- and b-neurexins (top), and composition
of recombinant Ig fusion proteins used for affinity purifications (bot-
tom). Abbreviations: SP, signal peptide; LG1 to LG6, laminin G do-
mains 1 to 6 (also called LNS domains for laminin/neurexin/sex
hormone binding globulin domains); E, EGF-like sequences; S, car-
bohydrate attachment site; T, transmembrane region. Numbered
arrows identify positions of canonical sites of alternative splicing;
in the Ig fusion proteins, 1 and 2 signs identify the presence or ab-
sence of inserts in the corresponding sites of alternative splicing.
(B) Affinity chromatography experiments. Solubilized proteins from
total rat brain homogenate (lane 1) were applied to a column con-
taining immobilized Ig control (Ig-C), Ig-N1a-1, and Ig-N1b-1, and
the flowthrough was collected (lane 2). The column was washed ex-
tensively with loading buffer (lanes 3–5) and eluted with 0.5 M NaCl
(data not shown) and 1.0 M NaCl (lanes 6–8). Fractions were ana-
lyzed by SDS-PAGE and silver staining. The major specific bands
(labeled 1–3 on the gel) were identified by mass spectroscopy as
indicated on the right (‘‘MS Identification’’).
(C) Immunoblotting analysis of proteins bound to Ig-C, Ig-N1a-1,
and Ig-N1b-1 and eluted in high salt.binding to neuroligins, with a-neurexins performing
additional roles via interactions that are not mediated
by b-neurexins and that may explain the a-neurexin
KO phenotype (Missler et al., 2003).
Figure 2. Regulation of Neurexin Binding by Alternative Splicing of
Neuroligin 1
(A) Domain structure of neuroligins (top), and composition of re-
combinant Flag-tagged neuroligins used as ligands for neurexins
(bottom). Abbreviations: SP, signal peptide; AchE-domain, acetyl-
cholinesterase-like domain including the dimerization sequence;
S, O-linked carbohydrate attachment site; T, transmembrane re-
gion; arrows labeled ‘‘A’’ and ‘‘B’’ identify positions of canonical al-
ternative splice sites, with 1 and 2 signs signifying the presence or
absence of an insert in the corresponding site.
(B) Pull-down of recombinant neuroligin 1 variants by immobilized
Ig neurexin fusion proteins. Secreted neuroligins from the medium
of transfected COS cells were bound to the neurexin Ig fusion
proteins indicated on top of the diagram (Ig-N1a-1 and -41 and
Ig-N1b-1 and -3 contain the full-length extracellular sequences of
neurexins 1a and 1b without and with an insert in splice site 4, re-
spectively; see Figure 4A). Bound neuroligins were visualized by
immunoblotting with an NL1-specific antibody.
(C) Binding analysis using surface plasmon resonance. Indicated
neuroligin 1 splice variants (111 nM) were injected over Ig neurexin
surfaces for 150 s, followed by buffer alone. Three curves gener-
ated by the same NL1 injection over surfaces containing the three
different neurexins were overlaid in each panel.
(D) Comparison of the apparent neuroligin 1 affinities of neurexin 1b
with neurexin 1a containing (Ig-N1a-41) or lacking (Ig-N1a-1) an in-
sert in splice site 4 (n 5 3 injections; RU, resonance unit). Error bars
represent means6 SDs. Note that only neuroligin 1 variants lacking
an insert in splice site B were tested because, with an insert in
splice site B, no neuroligin 1 binding to neurexin 1a was detected.
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We chose a biochemical approach to search for endog-
enous ligands of a-neurexins. We produced Ig fusion
proteins that include almost the entire extracellular do-
mains of neurexin 1a (Ig-N1a-1) or neurexin 1b (Ig-N1b-
1), and an Ig control protein (Ig-C) that contains only
the 18 N-terminal residues of mature neurexin 1a
(Figure 1A). We then performed affinity chromatography
experiments with rat brain proteins on the Ig fusion pro-
teins that were immobilized on protein A-Sepharose
and analyzed the eluents on silver-stained SDS poly-
acrylamide gels (Figure 1B). A heterogeneous group
of proteins of w90–120 kDa and a single protein of
w50 kDa were purified on neurexin 1a, while only the
w90–120 kDa proteins were bound to neurexin 1b.
Mass spectroscopy showed that thew90–120 kDa pro-
teins purified on neurexin 1a included neuroligins 1 and
2 and a-dystroglycan, and thew50 kDa band was com-
posed of b-dystroglycan, while the w90–120 kDa pro-
teins purified on neurexin 1b contained neuroligins 1,
2, and 3 but not a-dystroglycan. No significant binding
of a protein to the Ig control column was detected, ex-
cept for IgG heavy and light chains (IgG-HC and IgG-
LC) that were present in all eluents, presumably
because endogenous IgG in the brain homogenates
bound to protein A-Sepharose (Figure 1B). No other
proteins with extracellular sequences were identified
in the neurexin affinity-purified fractions, suggesting
that only neuroligins and dystroglycan tightly interact
with neurexin 1a, and only neuroligins tightly bind to
neurexin 1b.
Immunoblotting confirmed specific binding of brain
neuroligins 1 and 2 to both neurexin 1a and neurexin
1b, whereas dystroglycan only bound to neurexin 1a
(Figure 1C), and control membrane proteins such as
SynCAM did not bind to any neurexin (data not shown).
Moreover, binding of full-length recombinant neuro-
ligins 2 and 3 to immobilized neurexin 1a further corrob-
orated general binding of neuroligins to a-neurexins
(Figure S1 in the Supplemental Data available with this
article online). Finally, we also tested whether endoge-
nous a-neurexins in brain can be affinity purified on im-
mobilized recombinant neuroligin 1. In the neuroligin 1
eluent, we observed a single major protein of w175
kDa that was absent from control eluent (Figure S2),
and was found by sequencing to contain a mixture of
neurexins 1a, 2a, and 3a. In conjunction with the experi-
ments of Figure 1 and Figure S1, these results indicate
that a-neurexins generally interact with neuroligins.
Conceptually, the idea that neuroligins bind to a-
neurexins is attractive because binding of neuroligins
to both a- and b-neurexins would suggest a general
function of all neurexins in neuroligin-dependent trans-
synaptic cell adhesion. However, different from the
present affinity chromatography experiments, we pre-
viously failed to uncover binding of a-neurexins to neu-
roligin 1 (Ichtchenko et al., 1995). To address this
discrepancy, we produced recombinant neuroligin 1
proteins that were tagged with an N-terminal Flag
epitope and were truncated after the dimerization se-
quence at the C terminus of the acetylcholinesterase-
like domain (Figure 2A). Since neuroligin 1 possesses
two alternatively spliced sequences referred to as splicesites A and B (Ichtchenko et al., 1995), we tested the
binding of all four splice combinations of neuroligin 1
to immobilized neurexin Ig fusion proteins. In these ex-
periments, we examined neurexin 1a and 1b variants
that either included (Ig-N1a-41 and Ig-N1b-3) or lacked
an insert in splice site 4 (Ig-N1a-1 and Ig-N1b-1), and
used Ig-C as a control. We observed that neuroligin 1
containing an insert in splice site B—with or without
an insert in splice site A—exclusively bound to neurexin
1b lacking an insert in splice site 4. In contrast, neuroli-
gin 1 lacking an insert in splice site B—again with or
without an insert in splice site A—bound to both neu-
rexin 1a and 1b, and to both of the splice variants tested
for either neurexin (Figure 2B).
These results suggest that alternative splicing of neu-
roligin 1 at splice site B (which involves insertion or de-
letion of eight residues that are completely conserved in
mammals) regulates its binding to neurexins. To confirm
this possibility, we immobilized purified neuroligins on
agarose beads containing anti-Flag antibodies and ex-
amined the binding of soluble Ig neurexins (Figure S3).
Bound Ig proteins were probed with anti-human IgG
antibody. The results of the neuroligin pull-downs repli-
cated those of the neurexin pull-downs with one excep-
tion: the neuroligin pull-downs detected weak binding
of insert-positive b-neurexin to immobilized splice site
B-containing neuroligin 1 (Figure S3), whereas the neu-
rexin pull-downs did not (Figure 2B). This result indi-
cates that insert-positive neuroligin 1 exhibits a low
but finite affinity for insert-positive neurexin 1b.
To quantify better the information obtained with clas-
sical pull-down assays, we monitored binding between
neuroligin 1 and the neurexin 1a with or without splice
insert 4 by surface plasmon resonance (SPR). For com-
plete comparisons, equimolar amount of Ig-N1b-1,
Ig-N1a-1, and Ig-N1a-41 were coupled to a CM5 micro-
chip, and the same concentration of the four neuroligin 1
splice variants was injected. As suggested by the pull-
downs, only neuroligin 1 lacking the splice site B insert
(irrespective of the presence of splice insert A) bound to
both splice variants of Ig-N1a, indicating an absolute in-
hibitory function of splice insert B (Figure 2C). Since
measurements of association are made in real time, af-
finities can be estimated by comparing the maximum
binding of the same nonsaturating concentration in
each condition. This comparison demonstrated that
the absolute affinity of neurexin 1a for neuroligin 1 lack-
ing splice site B is w2-fold lower than that of neurexin
1b and is additionally regulated (againw2-fold) by alter-
native splicing of neurexin 1a at splice site 4 (Figure 2D).
Finally, to further confirm the affinity chromatography
and SPR conclusions by yet another assay, we ex-
pressed all four splice site combinations of full-length
Flag-tagged neuroligin 1 in HEK293 cells. We then
bound recombinant Ig fusion proteins of neurexins to
the transfected cells, using Ig-C as a control. We fixed
the cells without detergent permeabilization and stained
them by immunofluorescence for the Ig fusion proteins
(to measure binding of the Ig fusion proteins) and for
neuroligin 1 (to ensure that the various neuroligins
were expressed on the cell surface). We found that neu-
rexin 1b, irrespective of whether splice site 4 contained
or lacked an insert, specifically bound to all neuroligin 1
splice variants. In contrast, neurexin 1a variants only
Neuron
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No binding of Ig control protein to any neuroligin 1 var-
iant was detected (Figure 3), and no binding of any Ig
neurexin fusion protein to HEK293 cells that do not ex-
press a neuroligin 1 was observed (data not shown).
These data agree well with the affinity chromatography
and SPR results, except that the splice site B-positive
variant of neuroligin 1 now also bound to neurexin
1b containing an insert in splice site 4 (and not only
to neurexin 1b lacking an insert in splice site 4). This
discrepancy is probably due to the fact that the alterna-
tive splicing of b-neurexins and the alternative splicing
of neuroligins do not produce all-or-none effects but
change the binding affinities to different extents, and
that the affinity chromatography experiments are more
Figure 3. Binding of Ig Neurexins to Neuroligin 1 Splice Variants
Expressed on the Surface of HEK293 Cells
Full-length neuroligin 1 either containing an insert in both splice site
A and splice site B (NL1; [A]), lacking an insert in either splice site A
(NL1DA; [B]) or B (NL1DB; [C]), or lacking an insert in both splice
site A and splice site B (NL1DA,B; [D]) were expressed in trans-
fected HEK293 cells. Transfected cells were fixed in the absence
of detergent and incubated with 0.15 mM Ig neurexins or Ig control
proteins. Cell surface proteins were visualized with antibodies to
the Flag epitope (red) or to human Ig (green). In all panels, the right
images show the merged picture of the two labeling reactions, with
coincident labeling shown in yellow.stringent, while the SPR and cell surface binding experi-
ments are more sensitive.
By what mechanism does the splice site B insert reg-
ulate binding of neuroligin 1 to neurexins? To address
this question, we investigated whether neurexin 1a
and 1b bind to neuroligin 1 via a similar interaction. In
neurexin 1b, both the LG domain and a short b-specific
N-terminal sequence are required for neuroligin 1 bind-
ing (Nguyen and Su¨dhof, 1997). To dissect the binding
site of neurexin 1a for neuroligin 1, we produced a series
of Ig fusion proteins of a-neurexins that incorporate
a subset of domains with selected splice variants
(Figure 4A) and analyzed their binding to recombinant
neuroligins using affinity chromatography (Figure 4B).
Only neurexin 1a fragments that included both the third
EGF-like sequence and the sixth LG domain were able
to bind to neuroligin 1. Thus, in neurexin 1a and 1b,
binding of neuroligin 1 is mediated by the combined ac-
tion of an LG domain that is shared between neurexin 1a
and 1b, and of a sequence N-terminal to the LG domain
that differs between neurexin 1a and 1b.
We then examined how the insert sequence of splice
site B restricts a-neurexin binding. Interestingly, this se-
quence includes an N-glycosylation site at asparagine
Figure 4. Binding Site in Neurexin 1a for Neuroligin 1
(A) Domain structures of a- and b-neurexins, and structures of neu-
rexin Ig fusion proteins used for mapping the neuroligin binding site
on neurexins. Please see the legend to Figure 1A for an explanation
of the abbreviations used.
(B) Equivalent molar amounts of the immobilized Ig neurexin fusion
proteins were incubated with 0.1 mg of NL1DA,B* (truncated
secreted neuroligin 1 lacking inserts in splice sites A and B; see
Figure 2A) in the presence of Ca21. Bound proteins were analyzed
by SDS-PAGE and immunoblotting for neuroligin 1 (top), and Ig
proteins were assessed by Coomassie blue staining (bottom).
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chain (Hoffman et al., 2004) and decreases the affinity
of neuroligin 1 for insert-negative b-neurexins (Como-
letti et al., 2003). To test whether N-glycosylation of
the splice site B insert generally regulates neurexin
binding, we investigated the effect of deglycosylation
of neuroligin 1 on a-neurexin binding (Figure S4). We
found that deglycosylation strongly activated neurexin
1a binding to neuroligin 1 containing an insert in splice
site B, demonstrating that N-glycosylation at this site
controls the binding specificity of neuroligin 1.
The definition of neuroligin 1 splice variants that bind
either to only b-neurexins or to both a- and b-neurexins,
provides an opportunity to test the functional signifi-
cance of these interactions. We first tested both splice
variants in the artificial synapse formation assay but
detected no major difference between the two splice
variants (Figure S5). We next transfected cultured
hippocampal neurons with either EGFP (as a negative
control) or EGFP-tagged neuroligin 1 containing (NL1-
EGFP) or lacking (NL1DAB-EGFP) inserts in splice sites
A and B. Four days later, the neurons were fixed, stained
with antibodies to synapsin and MAP2 (as presynaptic
and dendritic markers, respectively), and analyzed by
confocal microscopy (Figure 5A). As expected, neuroli-
gin 1-EGFPs were highly enriched in dendritic spines
opposite to presynaptic terminals (arrows in Figure
5A), whereas EGFP not fused to neuroligin 1 was pres-
ent in both dendrites and spines.
To quantitate the effects of the transfected proteins,
we analyzed two parameters: the number of synapses
and spines per dendrite length, and the size of presyn-
aptic terminals and spines. These analyses were
performed in multiple independent transfection experi-
ments and ‘‘blindly’’ in that the experimenter was
unaware of the nature of transfected proteins.
Surprisingly, we found that, compared to EGFP trans-
fection alone, neuroligin 1 containing splice site inserts
induced a >2-fold increase in synapse numbers,
whereas neuroligin 1 lacking splice site inserts was
much less potent (Figure 5B). In contrast, neuroligin 1
lacking splice site inserts was significantly more effec-
tive in increasing the size of spines and presynaptic ter-
minals than neuroligin 1 containing splice site inserts.
The dramatic difference between the two splice variants
of neuroligin 1 was not simply due to a difference in ex-
pression as evidenced by two facts: (1) the EGFP signal
was similar, and (2) each of the two splice variants is
more potent than the other in one of the two parameters
analyzed. These data demonstrate that alternative
splicing of neuroligin 1, presumably by preventing or
promoting binding of a-neurexins in addition to b-
neurexins, has a profound effect on trans-synaptic
signaling.
Discussion
In the present study, we show the following: (1) neurexin
1a tightly binds two cell surface proteins, dystroglycan,
as shown previously (Sugita et al., 2001), and neuroli-
gins 1–3 (Figure 1 and Figures S1 and S2); (2) the in-
teraction of neurexin 1a and 1b with neuroligin 1 is
regulated by alternative splicing at site B of neuroligin
1 in an all-or-none fashion, and by alternative splicingat site 4 of neurexin in a gradual fashion (Figure 2 and
Figure S3); (3) alternative splicing at site B of neuroligin
1 controls a-neurexin binding by a glycosylation-depen-
dent mechanism (Figure 2); and (4) neuroligin 1 splice
variants that either bind only b-neurexins or both a-
and b-neurexins have profoundly different effects on
synapse size and density when expressed in neurons
(Figure 5). This last point is particularly important be-
cause it indicates that presynaptic activation of a- and
Figure 5. Effect of Neuroligin 1 Splice Variants that Bind Either
Only to b-Neurexins or to Both a- and b-Neurexins in Transfected
Neurons
(A) Representative fluorescence images of neurons transfected
with EGFP-tagged neuroligin 1 containing (NL1-EGFP) or lacking
(NL1DAB-EGFP) inserts in splice sites A and B, and of EGFP alone
as a negative control. Images show the EGFP fluorescence (green),
synapsin (red), and MAP2 immunofluorescence (blue), and the
merged view of all three fluorescence pictures. Note that neuroli-
gin 1 is exclusively present in spines, while EGFP is located in both
dendrites and spines, and that the signals for neuroligins in spines
and synapsin in nerve terminals are adjacent but not coincident (ar-
rows). Calibration bar in bottom left corner applies to all panels.
(B) Quantitative analysis of the synapse density on dendrites of
transfected neurons and of the synapse size on these dendrites.
Both synapse density and size were measured by observers un-
aware of the transfected molecule using spine fluorescence (due
to the neuroligin-EGFP fusion proteins) and presynaptic nerve ter-
minal fluorescence (visualized by synapsin immunostaining). Aster-
isks above the bar diagrams indicate statistical significance of
differences in pairwise comparisons between the three types of
transfections (n 5 3; *p < 0.05; **p < 0.01; ***p < 0.001; ns, nonsig-
nificant). Error bars represent means 6 SEMs.
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functional consequences. Viewed together, our data re-
veal a general interaction of both a- and b-neurexins
with neuroligins and suggest that this interaction repre-
sents a fundamental trans-synaptic adhesion mecha-
nism. Our data indicate that the combination of
neurexin and neuroligin variants at a synapse repre-
sents a trans-synaptic recognition code that shapes
the properties of that synapse and the corresponding
circuit.
The binding of neuroligins to a-neurexins was unex-
pected because earlier studies suggested that neuroli-
gins only bind to b-neurexins (Ichtchenko et al., 1995,
1996; Nguyen and Su¨dhof, 1997). This discrepancy is
explained by the fact that we previously employed
only the neuroligin 1 variant with an insert in splice site
B that, as we confirmed here, is indeed specific for b-
neurexins. In contrast, we now find that neuroligin 1
(and neuroligins 2 and 3) lacking an insert in splice site
B avidly bind to both a- and b-neurexins (Figures 2
and 3; Figure S1). Consistent with the common binding
of a- and b-neurexins to neuroligins, we found that neu-
rexin 1a bound neuroligin 1 via the same LG domain that
mediates neuroligin 1 binding in neurexin 1b (Figure 4).
It was previously shown in KO mice that a-neurexins
are essential for synaptic transmission even when
b-neurexins are present (Missler et al., 2003; Zhang
et al., 2005). Thus, the functions of a- and b-neurexins
do not completely overlap. This conclusion is reinforced
by our present finding that neuroligin 1 variants that
bind either only b-neurexins or both a- and b-neurexins
exert differential effects on synapse formation. At the
same time, both neuroligin 1 splice variants cause dra-
matic changes in synapse formation, indicating that
both a- and b-neurexins act as trans-synaptic cell adhe-
sion molecules by binding to neuroligins. The fact that
a-neurexins perform additional functions beyond the
common role of a- and b-neurexins suggests an ex-
planation for the divergent functions observed in a-
neurexin KO mice versus b-neurexin overexpression
studies, namely that a- and b-neurexins have a general
role in synapse formation mediated by neuroligin bind-
ing, a role that is still operative in the a-neurexin KO
mice because these mice continue to express b-neurex-
ins, and that a-neurexins have a special additional func-
tion in synapse organization. The special function of
a-neurexins is presumably executed via other ligands,
possibly dystroglycan and/or neurexophilins, or as yet
unidentified cell surface proteins. This function could
consist of a role in synapse formation as suggested by
RNA interference experiments of neuroligins (Chih
et al., 2005), although the lack of redundancy among
neuroligins in these experiments is puzzling considering
the redundancy among a-neurexins (Missler et al.,
2003). Alternatively, this shared function could specify
the balance between excitatory and inhibitory synapses
as suggested by transfection experiments (Prange
et al., 2004).
It is remarkable that the insertion or exclusion of only
eight residues in splice site B of neuroligin 1 activates or
blocks a-neurexin binding but leaves b-neurexin bind-
ing intact. We showed that in a- and b-neurexins the
neuroligin binding sites include the same C-terminal
LG domain but require different N-terminal sequences,suggesting that these N-terminal sequences are re-
sponsible for the distinct neuroligin 1 binding properties
of a- and b-neurexins. In neuroligin 1, the splice site B
insert appears to block a-neurexin binding via glycosyl-
ation because the insert sequence contains a conserved
N-glycosylation site, and because deglycosylation of
neuroligin 1 activates a-neurexin binding (Figure S4).
On top of the regulation of a- and b-neurexin binding
by alternative splicing of neuroligin 1, the affinity of a-
and b-neurexin binding to neuroligins is modulated
w2-fold by alternative splicing of neurexins at splice
site 4 (Figure 2). It thus seems likely that trans-synaptic
signaling by the neurexin/neuroligin complex may be
controlled by a hierarchy of regulatory events: transcrip-
tion (a- versus b-neurexins, different types of neuroli-
gins), alternative splicing of neuroligin 1 at site B, and
alternative splicing of neurexins at site 4. Such a hierar-
chy of regulatory events would be well suited to contrib-
ute to shaping the properties of synaptic circuits,
a possibility that will have to be explored in future ex-
periments using genetic approaches that allow studying
more physiological changes.
Experimental Procedures
Production of Recombinant Neurexins and Neuroligins
Neurexins
Neurexins were produced as Ig fusion proteins encoded by a series
of constructs (Figure 4A) that were largely reported previously (Ush-
karyov et al., 1994; Sugita et al., 2001; Missler et al., 1998a) and are
described in detail in the Supplemental Data. Ig proteins were puri-
fied on protein-A Sepharose from the media of transfected COS
cells and either used directly or eluted with 0.1 M glycine (pH 2.2).
Neuroligins
Neuroligins were produced as a series of secreted truncated pro-
teins (Figure 2A) with an N-terminal Flag tag essentially as described
(Comoletti et al., 2003), or as full-length proteins lacking or contain-
ing EGFP inserted into the cytoplasmic sequence. See the Supple-
mental Data for a detailed account of the constructs and methods
used.
Brain Affinity Chromatography
Brain affinity chromatography was performed with brain proteins
solubilized in 1% Triton X-100 essentially as described (Ichtchenko
et al., 1995) with modifications (see Supplemental Data). Proteins
bound to the neurexin or neuroligin affinity matrices were identified
by mass spectrometry analysis (UTSouthwestern Protein Identifica-
tion Facility), and identifications were confirmed by immunoblotting.
Pull-Down Assays
Pull-down assays were performed with immobilized Ig neurexins or
Flag-tagged neuroligins essentially as described (Sugita et al.,
2001).
SPR Analysis of the NL1-NX1a Complex
NL1 binding was analyzed at 25ºC using 10 mM HEPES buffer (pH
7.4) containing 2 mM CaCl2 and 0.005% (v/v) surfactant P20, on
a BIAcore 3000 apparatus. Protein A (Sigma) was covalently bound
to the carboxymethylated dextran matrix of a CM5 chip (BIAcore,
Uppsala, Sweden), and IgG-neurexin was indirectly captured by
protein A via its IgG portionw10,000 resonance units (RU). A sepa-
rate reference surface containing protein A was coupled with IgC
protein. Reference data were subtracted from the sample flow
channel to obtain specific NX1a binding. NL1 was injected at con-
centrations ranging from 3000 to 12 nM in 3-fold dilution.
Neurexin Cell Surface Binding Assays
Transfected HEK293T cells expressing full-length neuroligins in all
four splice combinations were incubated in DMEM containing
20 mM HEPES-NaOH (pH 7.4), 0.1% BSA, and 0.15 mM of either
trans-Synaptic Neurexin/Neuroligin Complex
235IgC, IgN1a-1, IgN1a-41, IgN1b-1, or IgN1b-3 for 16 hr at 4ºC,
washed, and fixed with 4% paraformaldehyde in the absence of de-
tergent. Cells were then reacted with mouse M2 Flag antibody, and
bound Ig fusion proteins and Flag antibodies were visualized with
secondary antibodies and analyzed by confocal microscopy.
Primary Neuronal Culture, Transfection, and
Immunocytochemistry
Primary hippocampal neuronal cultures from newborn (P1) rats (Ka-
valali et al., 1999) were transfected with NL1-EGFP, NL1-DAB-
EGFP, and EGFP constructs at 10 days in vitro (DIV) and analyzed
at 14 days DIV by immunofluorescence staining for synapsin and
MAP2 (see Supplemental Data). Stacks of z-section images ob-
tained by confocal microscopy were converted to maximal projec-
tion images and analyzed blindly using NIH Image/ImageJ
program, with area size, fluorescent intensity, and density of spines
and presynaptic terminals per 50 mm of dendrite measured using the
‘‘Analyze particle’’ module. Statistical significance was determined
by Student’s t test.
Miscellaneous
SDS-PAGE and immunoblotting were performed using standard
procedures; most antibodies employed were previously character-
ized (Sugita et al., 2001; Ichtchenko et al., 1995; Song et al., 1999;
Biederer et al., 2002; Ushkaryov et al., 1992). To achieve deglycosy-
lation, 10–15 mg of NL1 in 200 ml was incubated with PNGase F
(Glyko, Novato, CA) for 10 hr at 37ºC.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and five supplemental figures and can be found with this ar-
ticle online at http://www.neuron.org/cgi/content/full/48/2/229/
DC1/.
Acknowledgments
We thank Dr. E. Kavalali (UT Southwestern, Dallas) for advice. This
study was supported by a grant from the NIMH (R37 MH52804-08
to T.C.S.), a postdoctoral fellowship from Fonds de la Recherche
en Sante´ du Que´bec (FRSQ; to A.A.B.), and a grant from Cure Au-
tism Now to D.C.
Received: March 28, 2005
Revised: July 11, 2005
Accepted: August 19, 2005
Published: October 19, 2005
References
Biederer, T., Sara, Y., Mozhayeva, M., Atasoy, D., Liu, X., Kavalali,
E.T., and Su¨dhof, T.C. (2002). SynCAM, a synaptic adhesion mole-
cule that drives synapse assembly. Science 297, 1525–1531.
Chih, B., Engelman, H., and Scheiffele, P. (2005). Control of excit-
atory and inhibitory synapse formation by neuroligins. Science
307, 1324–1328.
Comoletti, D., Flynn, R., Jennings, L.L., Chubykin, A., Matsumura,
T., Hasegawa, H., Su¨dhof, T.C., and Taylor, P. (2003). Characteriza-
tion of the interaction of a recombinant soluble neuroligin-1 with
neurexin-1b. J. Biol. Chem. 278, 50497–50505.
Dean, C., Scholl, F.G., Choih, J., DeMaria, S., Berger, J., Isacoff, E.,
and Scheiffele, P. (2003). Neurexin mediates the assembly of pre-
synaptic terminals. Nat. Neurosci. 6, 708–716.
Fu, Z., Washbourne, P., Ortinski, P., and Vicini, S. (2003). Functional
excitatory synapses in HEK293 cells expressing neuroligin and glu-
tamate receptors. J. Neurophysiol. 90, 3950–3957.
Graf, E.R., Zhang, X., Jin, S.X., Linhoff, M.W., and Craig, A.M.
(2004). Neurexins induce differentiation of GABA and glutamate
postsynaptic specializations via neuroligins. Cell 119, 1013–1026.
Hoffman, R.C., Jennings, L.L., Tsigelny, I., Comoletti, D., Flynn,
R.E., Sudhof, T.C., and Taylor, P. (2004). Structural characterization
of recombinant soluble rat neuroligin 1: mapping of secondarystructure and glycosylation by mass spectrometry. Biochemistry
43, 1496–1506.
Ichtchenko, K., Hata, Y., Nguyen, T., Ullrich, B., Missler, M., Moo-
maw, C., and Su¨dhof, T.C. (1995). Neuroligin 1: A splice site-spe-
cific ligand for b-neurexins. Cell 81, 435–443.
Ichtchenko, K., Nguyen, T., and Su¨dhof, T.C. (1996). Structures,
alternative splicing, and neurexin binding of multiple neuroligins.
J. Biol. Chem. 271, 2676–2682.
Jamain, S., Quach, H., Betancur, C., Rastam, M., Colineaux, C., Gill-
berg, I.C., Soderstrom, H., Giros, B., Leboyer, M., Gillberg, C., and
Bourgeron, T. (2003). Mutations of the X-linked genes encoding
neuroligins NLGN3 and NLGN4 are associated with autism. Nat.
Genet. 34, 27–29.
Kattenstroth, G., Tantalaki, E., Su¨dhof, T.C., Gottmann, K., and
Missler, M. (2004). Postsynaptic N-methyl-D-aspartate receptor
function requires a-neurexins. Proc. Natl. Acad. Sci. USA 101,
2607–2612.
Kavalali, E.T., Klingauf, J., and Tsien, R.W. (1999). Activity-depen-
dent regulation of synaptic clustering in a hippocampal culture sys-
tem. Proc. Natl. Acad. Sci. USA 96, 12893–12900.
Missler, M., Hammer, R.E., and Su¨dhof, T.C. (1998a). Neurexophilin
binding to a-neurexins. A single LNS domain functions as an inde-
pendently folding ligand-binding unit. J. Biol. Chem. 273, 34716–
34723.
Missler, M., Fernandez-Chacon, R., and Su¨dhof, T.C. (1998b). The
making of neurexins. J. Neurochem. 71, 1339–1347.
Missler, M., Zhang, W., Rohlmann, A., Kattenstroth, G., Hammer,
R.E., Gottmann, K., and Su¨dhof, T.C. (2003). a-neurexins couple
Ca21 channels to synaptic vesicle exocytosis. Nature 423, 939–948.
Moore, S.A., Saito, F., Chen, J., Michele, D.E., Henry, M.D., Mess-
ing, A., Cohn, R.D., Ross-Barta, S.E., Westra, S., Williamson,
R.A., et al. (2002). Deletion of brain dystroglycan recapitulates as-
pects of congenital muscular dystrophy. Nature 418, 422–425.
Nguyen, T., and Su¨dhof, T.C. (1997). Binding properties of neuroli-
gin 1 and neurexin 1b reveal function as heterophilic cell adhesion
molecules. J. Biol. Chem. 272, 26032–26039.
Prange, O., Wong, T.P., Gerrow, K., Wang, Y.T., and El-Husseini, A.
(2004). A balance between excitatory and inhibitory synapses is
controlled by PSD-95 and neuroligin. Proc. Natl. Acad. Sci. USA
101, 13915–13920.
Rowen, L., Young, J., Birditt, B., Kaur, A., Madan, A., Philipps, D.L.,
Qin, S., Minx, P., Wilson, R.K., Hood, L., and Graveley, B.R. (2002).
Analysis of the human neurexin genes: alternative splicing and the
generation of protein diversity. Genomics 79, 587–597.
Scheiffele, P., Fan, J., Choih, J., Fetter, R., and Serafini, T. (2000).
Neuroligin expressed in nonneuronal cells triggers presynaptic
development in contacting axons. Cell 101, 657–669.
Song, J.Y., Ichtchenko, K., Su¨dhof, T.C., and Brose, N. (1999). Neu-
roligin 1 is a postsynaptic cell-adhesion molecule of excitatory syn-
apses. Proc. Natl. Acad. Sci. USA 96, 1100–1105.
Sugita, S., Saito, F., Tang, J., Satz, J., Campbell, K., and Sudhof,
T.C. (2001). A stoichiometric complex of neurexins and dystrogly-
can in brain. J. Cell Biol. 154, 435–445.
Tabuchi, K., and Su¨dhof, T.C. (2002). Structure and evolution of
neurexin genes: insight into the mechanism of alternative splicing.
Genomics 79, 849–859.
Ullrich, B., Ushkaryov, Y.A., and Su¨dhof, T.C. (1995). Cartography
of neurexins: More than 1000 isoforms generated by alternative
splicing and expressed in distinct subsets of neurons. Neuron 14,
497–507.
Ushkaryov, Y.A., Petrenko, A.G., Geppert, M., and Su¨dhof, T.C.
(1992). Neurexins: synaptic cell surface proteins related to the a-
latrotoxin receptor and laminin. Science 257, 50–56.
Ushkaryov, Y.A., Hata, Y., Ichtchenko, K., Moomaw, C., Afendis, S.,
Slaughter, C.A., and Su¨dhof, T.C. (1994). Conserved domain struc-
ture of b-neurexins. Unusual cleaved signal sequences in receptor-
like neuronal cell-surface proteins. J. Biol. Chem. 269, 11987–
11992.
Neuron
236Varoqueaux, F., Jamain, S., and Brose, N. (2004). Neuroligin 2 is ex-
clusively localized to inhibitory synapses. Eur. J. Cell Biol. 83, 449–
456.
Yamagata, M., Sanes, J.R., and Weiner, J.A. (2003). Synaptic adhe-
sion molecules. Curr. Opin. Cell Biol. 15, 621–632.
Yan, J., Oliveira, G., Coutinho, A., Yang, C., Feng, J., Katz, C., Sram,
J., Bockholt, A., Jones, I.R., Craddock, N., et al. (2004). Analysis of
the neuroligin 3 and 4 genes in autism and other neuropsychiatric
patients. Mol. Psychiatry 10, 329–332.
Zhang, W., Rohlmann, A., Sargsyan, V., Aramuni, G., Hammer, R.E.,
Su¨dhof, T.C., and Missler, M. (2005). Extracellular domains of a-
neurexins participate in regulating synaptic transmission by selec-
tively affecting N-and P/Q-type Ca21-channels. J. Neurosci. 25,
4330–4342.
